Going All In on mRNA, Sanofi Breaks Ground on New Vaccine Site

On Monday, Sanofi laid the first stone in the construction of its Evolutive Vaccine Facility, which is expected to be a fully digitalized production site the company believes will “transform the way we make vaccines and treatments.”

In addition to the beginning of construction, Sanofi announced an investment of more than $1 billion into the development of new mRNA programs.